Profound Medical Corp (PRN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Profound Medical Corp (PRN) has a cash flow conversion efficiency ratio of -0.142x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CA$-11.77 Million ≈ $-8.52 Million USD) by net assets (CA$82.93 Million ≈ $59.99 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See PRN defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Profound Medical Corp - Cash Flow Conversion Efficiency Trend (2014–2025)
This chart illustrates how Profound Medical Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Profound Medical Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Profound Medical Corp ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Global Tax Free Co. Ltd
KQ:204620
|
0.123x |
|
Innoprise Plantations Bhd
KLSE:6262
|
0.065x |
|
Light S.A
SA:LIGT3
|
-0.019x |
|
SILENCE THERAP. SP.ADR/1
F:XRP2
|
-0.277x |
|
Ingevec
SN:INGEVEC
|
0.045x |
|
Mitra Pinasthika Mustika Tbk
JK:MPMX
|
0.041x |
|
HengFeng Information Technology Co Ltd
SHE:300605
|
0.084x |
|
Huuuge Inc.
WAR:HUG
|
0.127x |
Annual Cash Flow Conversion Efficiency for Profound Medical Corp (2014–2025)
The table below shows the annual cash flow conversion efficiency of Profound Medical Corp from 2014 to 2025. For the full company profile with market capitalisation and key ratios, see Profound Medical Corp stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CA$91.06 Million ≈ $65.87 Million |
CA$-53.39 Million ≈ $-38.62 Million |
-0.586x | -51.03% |
| 2024-12-31 | CA$60.42 Million ≈ $43.71 Million |
CA$-23.45 Million ≈ $-16.97 Million |
-0.388x | +46.47% |
| 2023-12-31 | CA$31.18 Million ≈ $22.56 Million |
CA$-22.61 Million ≈ $-16.36 Million |
-0.725x | -46.16% |
| 2022-12-31 | CA$52.00 Million ≈ $37.62 Million |
CA$-25.80 Million ≈ $-18.66 Million |
-0.496x | -78.87% |
| 2021-12-31 | CA$80.62 Million ≈ $58.32 Million |
CA$-22.36 Million ≈ $-16.17 Million |
-0.277x | -31.24% |
| 2020-12-31 | CA$97.35 Million ≈ $70.42 Million |
CA$-20.57 Million ≈ $-14.88 Million |
-0.211x | +80.31% |
| 2019-12-31 | CA$14.29 Million ≈ $10.34 Million |
CA$-15.33 Million ≈ $-11.09 Million |
-1.073x | -56.19% |
| 2018-12-31 | CA$19.55 Million ≈ $14.14 Million |
CA$-13.43 Million ≈ $-9.72 Million |
-0.687x | +34.59% |
| 2017-12-31 | CA$11.25 Million ≈ $8.13 Million |
CA$-11.81 Million ≈ $-8.55 Million |
-1.050x | -7.46% |
| 2016-12-31 | CA$11.04 Million ≈ $7.98 Million |
CA$-10.79 Million ≈ $-7.81 Million |
-0.977x | -98.96% |
| 2015-12-31 | CA$10.06 Million ≈ $7.28 Million |
CA$-4.94 Million ≈ $-3.58 Million |
-0.491x | +76.65% |
| 2014-12-31 | CA$1.37 Million ≈ $989.71K |
CA$-2.88 Million ≈ $-2.08 Million |
-2.104x | -- |
About Profound Medical Corp
Profound Medical Corp. operates as a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapeutic systems for the image guided ablation of diseased tissue. The company's lead product TULSA-PRO system combines magnetic resonance imaging (MRI), robotically driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedb… Read more